Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Jian Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Technology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, N…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Claudins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Jiangsu Provincial Medical Youth Talent, Graduate Research and Innovation Projects of Jiangsu Province, Project 333 of Jiangsu Province.
Abstract (Originalsprache)
Zolbetuximab (IMAB362), a monoclonal antibody targeting Claudin18.2 (CLDN 18.2), demonstrates a significant clinical benefit in patients with advanced gastroesophageal cancers. The noninvasive assessment of CLDN18.2 expression through molecular imaging offers a potential avenue for expedited monitoring and the stratification of patients into risk groups. This study elucidates that CLDN18.2 is expressed at a noteworthy frequency in primary gastric cancers and their metastases. The iodogen method was employed to label IMAB362 with 123I/131I. The results demonstrated the efficient and reproducible synthesis of 123I-IMAB362, with a specific binding affinity to CLDN18.2. Immuno-single-photon emission computed tomography (SPECT) imaging revealed the rapid accumulation of 123I-IMAB362 in gastric cancer xenografts at 12 h, remaining stable for 3 days in patient-derived tumor xenograft models. Additionally, tracer uptake of 123I-IMAB362 in MKN45 cells surpassed that in MKN28 cells at each time point, with tumor uptake correlating significantly with CLDN18.2 expression levels. Positron emission tomography/computed tomography imaging indicated that tumor uptake of 18F-FDG and the functional/viable tumor volume in the 131I-IMAB362 group were significantly lower than those in the 123I-IMAB362 group on day 7. In conclusion, 123I-IMAB362 immuno-SPECT imaging offers an effective method for direct, noninvasive, and whole-body quantitative assessment of tumor CLDN18.2 expression in vivo. This approach holds promise for accelerating the monitoring and stratification of patients with gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science and Technology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China.
- Department of Nuclear Medicine, The Affiliated Taizhou People's Hospital of Nanjing University of Chinese Medicine, Taizhou 225300, China.
- Department of Nuclear Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China.
ORCID-Profile: Jun Zhang
Förderung
- Jiangsu Provincial Medical Youth Talent
- Graduate Research and Innovation Projects of Jiangsu Province
- Project 333 of Jiangsu Province
- National Natural Science Foundation of China
- Science and Technology Support Program of Jiangsu Province
- Nanjing Medical Science and Technique Development Foundation
- Jiangsu Provincial High level health talent "six one project"
- Jiangsu Provincial Hospital of Traditional Chinese Medicine Academic Talent Program
Zitieren
APA
Wu, J., Chen, J., Zhao, Y., Yuan, M., Chen, X., He, X., Zhang, J., Shao, G., & Sun, Q. (2024). Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00155
Vancouver
Wu J, Chen J, Zhao Y, Yuan M, Chen X, He X, et al. Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00155
BibTeX
@article{Wu2024,
author = {Wu, Jian and Chen, Jun and Zhao, Yuetong and Yuan, Mengyun and Chen, Xu and He, Xiangdong and Zhang, Jun and Shao, Guoqiang and Sun, Qingmin},
title = {Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00155}
}
EUVIMED